TrialClinical drug investigation2020

Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.

Ramakrishna Nirogi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.